Inhibrx Biosciences, Inc. (INBX) — Financial Flexibility Index
Inhibrx Biosciences, Inc. (INBX) has a Financial Flexibility Index of -0.22x as of December 2025. Free cash flow of $-30.12 Million (operating CF $-30.12 Million minus capex $0.00) represents 0% of total liabilities ($138.49 Million). Also explore INBX shareholders equity momentum to track the company's year-over-year net asset growth rate.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Inhibrx Biosciences, Inc. Financial Flexibility Index (2016–2025)
Historical Financial Flexibility Index trend for Inhibrx Biosciences, Inc. across 10 annual periods. See debt-free asset ratio of Inhibrx Biosciences, Inc. to measure how much of total assets are equity-financed.
Annual Financial Flexibility Index for Inhibrx Biosciences, Inc. (2016–2025)
Year-by-year free cash flow to debt coverage for Inhibrx Biosciences, Inc.. For the full company profile including market capitalisation, see Inhibrx Biosciences, Inc. (INBX) total market value.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -0.94x | $-129.76 Million | $-129.79 Million | $138.49 Million | ▲ +77.0% |
| 2024 | -4.07x | $-191.81 Million | $-194.41 Million | $47.18 Million | ▼ -469.5% |
| 2023 | -0.71x | $-188.72 Million | $-193.31 Million | $264.39 Million | ▼ -45.0% |
| 2022 | -0.49x | $-114.61 Million | $-115.30 Million | $232.82 Million | ▲ +39.2% |
| 2021 | -0.81x | $-79.46 Million | $-80.32 Million | $98.07 Million | ▼ -18.7% |
| 2020 | -0.68x | $-46.60 Million | $-47.97 Million | $68.27 Million | ▼ -170.8% |
| 2019 | -0.25x | $-30.27 Million | $-32.08 Million | $120.06 Million | ▲ +21.3% |
| 2018 | -0.32x | $-21.66 Million | $-23.09 Million | $67.63 Million | ▲ +27.0% |
| 2017 | -0.44x | $-17.41 Million | $-18.75 Million | $39.67 Million | ▲ +50.9% |
| 2016 | -0.89x | $-17.89 Million | $-18.11 Million | $20.03 Million | — |